ACADEMIA

JAS 2012 GL Calls for Consideration of Medication for Primary Prevention in Patients with LDL-C Levels Over 180 mg/dL

February 7, 2012

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japan Atherosclerosis Society (JAS) announced at a forum held in Kagoshima City on February 5 the outline of the “prevention guideline (GL) for arteriosclerotic disease 2012”, for which the revision is in progress. The GL will indicate that medication…

To read the full story

New Atherosclerosis Guidelines Likely to Add PCSK9 Inhibitors for Primary Prevention of CAD in Familial Hypercholesterolemia
July 20, 2016

ACADEMIA

Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…